Tyme Technologies Stock Forecast, Price & News

-0.09 (-5.66 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume7.88 million shs
Average Volume3.83 million shs
Market Capitalization$195.65 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

Tyme Technologies logo

About Tyme Technologies

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.48 out of 5 stars

Medical Sector

1701st out of 2,099 stocks

Pharmaceutical Preparations Industry

727th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

Is Tyme Technologies a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tyme Technologies stock.
View analyst ratings for Tyme Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Tyme Technologies?

Wall Street analysts have given Tyme Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 5,510,000 shares, an increase of 21.4% from the May 13th total of 4,540,000 shares. Based on an average daily volume of 2,840,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 5.3% of the shares of the company are short sold.
View Tyme Technologies' Short Interest

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Tyme Technologies

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) posted its quarterly earnings results on Thursday, February, 4th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.02.
View Tyme Technologies' earnings history

How has Tyme Technologies' stock been impacted by Coronavirus?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TYME shares have increased by 42.9% and is now trading at $1.50.
View which stocks have been most impacted by COVID-19

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman & Chief Science Officer (Age 58, Pay $900.79k)
  • Mr. Richard Cunningham, CEO & Director (Age 50)
  • Mr. Frank L. Porfido, Chief Financial Officer (Age 57)
  • Ms. Barbara C. Galaini, Principal Accounting Officer & Corp. Controller (Age 63)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 57)
  • Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 47)
  • Mr. John Zucaro P.E., Sr. VP of CMC
  • Dr. John M. Rothman, Exec. VP of Product Devel. (Age 73)
  • Dr. Jan Marie-Albert Van Tornout M.D., M.Sc., Chief Medical Officer

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.45%), Healthcare Value Capital LLC (1.15%), Geode Capital Management LLC (0.98%), Northern Trust Corp (0.62%), Nuveen Asset Management LLC (0.33%) and HighTower Advisors LLC (0.28%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Michele Ilene Korfin, Steve Hoffman and Tornout Jan M Van.
View institutional ownership trends for Tyme Technologies

Which major investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC, and HighTower Advisors LLC. Company insiders that have sold Tyme Technologies company stock in the last year include Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
or view top insider-selling stocks.

Which major investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Morgan Stanley, Virtu Financial LLC, Millennium Management LLC, Edmond DE Rothschild Holding S.A., Axiom Investment Management LLC, and Axiom Investment Management LLC. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michele Ilene Korfin, Steve Hoffman, and Tornout Jan M Van.
View insider buying and selling activity for Tyme Technologies
or or view top insider-buying stocks.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.50.

How much money does Tyme Technologies make?

Tyme Technologies has a market capitalization of $195.65 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How many employees does Tyme Technologies have?

Tyme Technologies employs 18 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is

Where are Tyme Technologies' headquarters?

Tyme Technologies is headquartered at 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.